[1]Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma\[J\]. Cancer Immunol Res, 2014, 2(7):632-642.
[2]Chen L, Han X. AntiPD1/PDL1 therapy of human cancer: past, present, and future\[J\]. J Clin Invest,2015,125(9):3384-3391.
[3]Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the antiPDL1 antibody MPDL3280A in cancer patients\[J\]. Nature,2014,515(7528):563-567.
[4]Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer\[J\]. N Engl J Med,2012,366(26):2455-2465.
[5]Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in nonsmall cell lung cancer\[J\] Cancer Discov, 2017,7(3):264-276.
[6]Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD1/PDL1 targeted therapies\[J\]. J Clin Oncol, 2016,34(15):9017.
[7]Borghaei H, Brahmer J. Nivolumab in nonsquamous nonsmallcell lung cancer\[J\]. N Engl J Med,2016,374(5):493-494.
[8]Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmallcell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial\[J\]. Lancet, 2016, 387(10030):1837-1846.
[9]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer\[J\]. N Engl J Med,2012,366(26):2443-2454.
[10]Vitale SG, Lagan AS, Capriglione S, et al. Target therapies for uterine carcinosarcomas: current evidence and future perspectives\[J\]. Int J Mol Sci, 2017, 18(5):1100.
[11]Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity cycle\[J\]. Immunity, 2013, 39(1):1-10.
[12]Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma\[J\]. N Engl J Med, 2013, 369(2):122-133.
[13]McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade\[J\]. Science, 2016, 351(6280):1463-1469.
[14]Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline therapy in extensivediseasesmallcell lung cancer: results from a randomized, doubleblind, multicenter phase 2 trial\[J\]. Ann Oncol, 2013, 24(1):75-83.
[15]Choudhury N, Nakamura Y. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies\[J\]. Cancer Sci, 2016, 107(2):107-115.
[16]Schumacher TN, Scheper W. A liquid biopsy for cancer immunotherapy\[J\]. Nat Med, 2016, 22(4):340-341.
[17]Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer\[J\]. Clin Chem,2015,61(1):112-123.
[18]Cheng F, Su L, Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer\[J\]. Oncotarget,2016,7(30):48832-48841.
[19]Inoue H, Park JH, Kiyotani K, et al. Intratumoral expression levels of PDL1, GZMA, and HLAA along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma\[J\]. Oncoimmunology, 2016,5(9):e1204507.
[20]Shukuya T, Carbone DP. Predictive markers for the efficacy of antiPD1/PDL1 antibodies in lung cancer\[J\]. J Thorac Oncol, 2016,11(7):976-988.
[21]Larkin J, ChiarionSileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma\[J\]. N Engl J Med,2015,373(1):23-34.
[22]Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition\[J\]. Clin Cancer Res, 2016,22(8):1865-1874.
[23]Alexandrov LB, NikZainal S, Wedge DC, et al. Signatures of mutational processes in human cancer\[J\]. Nature, 2013,500(7463):415-421.
[24]Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on Tcell infiltration and PDL1\[J\]. Cancer Res,2015,75(11):2139-2145.
[25]Smyth MJ, Ngiow SF, Ribas A, et al. Combination cancer immunotherapies tailored to the tumour microenvironment\[J\]. Nat Rev Clin Oncol, 2016,13(3):143-158.
[26]Konishi J, Yamazaki K, Azuma M, et al. B7H1 expression on nonsmall cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD1 expression\[J\]. Clin Cancer Res, 2004,10(15):5094-5100.
[27]He Y, Yu H, Rozeboom L, et al. LAG3 Protein expression in nonsmall cell lung cancer and its relationship with PD1/PDL1 and tumorinfiltrating lymphocytes\[J\]. J Thorac Oncol, 2017, 12(5): 814-823.
[28]Zhang Y, Cai P, Liang T, et al. TIM3 is a potential prognostic marker for patients with solid tumors: A systematic review and metaanalysis\[J\]. Oncotarget, 2017,8(19):31705-31713.
[29]Liu XG, Hou M, Liu Y. TIGIT, a novel therapeutic target for tumor immunotherapy\[J\]. Immunol Invest, 2017,46(2):172-182.
[30]Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD1 blockade is associated with upregulation of alternative immune checkpoints\[J\]. Nat Commun,2016,7:10501.
[31]Inoue H, Park JH, Kiyotani K, et al. Intratumoral expression levels of PDL1, GZMA, and HLAA along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma\[J\]. Oncoimmunology, 2016,5(9):e1204507.
[32]Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigenspecific lymphocytes in the peripheral blood of melanoma patients\[J\]. Nat Med, 2016,22(4):433-438.
[33]Powles T, Eder JP, Fine GD, et al. MPDL3280A (antiPDL1) treatment leads to clinical activity in metastatic bladder cancer\[J\]. Nature,2014,515(7528):558-562.
[34]Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer\[J\]. Science, 2015,348(6230):62-68.
[35]Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD1 blockade in nonsmall cell lung cancer\[J\]. Science, 2015,348(6230):124-128.
[36]Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamousnonsmallcell lung cancer\[J\]. N Engl J Med,2015,373(17):1627-1639.
[37]Khodadoust MS, Olsson N, Wagar LE, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens\[J\]. Nature, 2017,543(7647):723-727.
[38]Zhang Y, Ma JA, Zhang Hx, et al. Cancer vaccines: Targeting KRASdriven cancer[J]. Expert Rev Vaccines, 2020,19(2):163-173.
[39]Cai LL, Ye HM, Zheng LM, et al. Circulating tumor cells(CTCs) as a liquid biopsy material and drug target\[J\]. Curr Drug Targets, 2014,15(10):965-972.
[40]Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimusinedvancedrenalcell carcinoma\[J\]. N Engl J Med, 2015,373(19):1803-1813. |